Imagia, Illumina partner to advance precision medicine

By The Science Advisory Board staff writers

June 22, 2020 -- Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using genomic and health data.

The collaboration is aimed at investigating precision medicine to decipher information on patient-specific biology. Real world patient data will be organized to better understand disease evolutions and improve patient outcomes with new management tools, particularly in the areas of genomic data analysis and artificial intelligence (AI) biomarker discovery.

Through the partnership, the two firms will create a database that can be used with medical imaging and drug development, and will make the data available via Illumina's Dragen Bio-IT and its Illumina Analytics platforms, as well as Imagia's Evidens advanced AI platform, the companies said.

Illumina acquires BlueBee to speed NGS
Illumina has acquired BlueBee, a Dutch genomics analysis software firm that originated as a spinoff from Delft University of Technology, in an effort...
Illumina makes SARS-CoV-2 NGS toolkit free of charge
Illumina is making its SARS-CoV-2 data toolkit, a suite of data analysis tools and workflow functionality, free for researchers researching the virus...
Illumina, IDbyDNA partner for COVID-19 surveillance
IDbyDNA and Illumina have partnered to bring next-generation sequencing (NGS) workflows to the global microbiology market to combat the COVID-19 pandemic....
NGS Informatics: Choosing the Superior Software Tool
As Next Generation Sequencing (NGS) continues to grow, scientists face many challenges in terms of their data analysis and storage solutions. Our members...
CRISPR - A New Era in Genome Editing
A major buzzword in the science world recently has been CRISPR: short for Clustered Regularly Interspaced Short Palindromic Repeats. This is a simple,...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter